{"pmid":32311763,"title":"Off-Label Therapies for COVID-19-Are We All In This Together?","text":["Off-Label Therapies for COVID-19-Are We All In This Together?","SARS-CoV-2 continues to spread rapidly outside of mainland China. As of April 6, there are over 300,000 cases and 10,000 deaths in the US. Effective therapies for the novel Coronavirus are urgently needed and over 200 clinical trials are now underway across the globe. Recognizing the need for robust randomized control trials, the World Health Organization (WHO) recently organized a multinational randomized trial-the SOLIDARITY trial-to study the effect of drugs that have been identified as promising based on in-vitro data and the early clinical experience with COVID-19: Remdesivir, lopinavir and ritonavir; lopinavir and ritonavir + interferon; and chloroquine or hydroxychloroquine.","Clin Pharmacol Ther","Alpern, Jonathan D","Gertner, Elie","32311763"],"abstract":["SARS-CoV-2 continues to spread rapidly outside of mainland China. As of April 6, there are over 300,000 cases and 10,000 deaths in the US. Effective therapies for the novel Coronavirus are urgently needed and over 200 clinical trials are now underway across the globe. Recognizing the need for robust randomized control trials, the World Health Organization (WHO) recently organized a multinational randomized trial-the SOLIDARITY trial-to study the effect of drugs that have been identified as promising based on in-vitro data and the early clinical experience with COVID-19: Remdesivir, lopinavir and ritonavir; lopinavir and ritonavir + interferon; and chloroquine or hydroxychloroquine."],"journal":"Clin Pharmacol Ther","authors":["Alpern, Jonathan D","Gertner, Elie"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311763","week":"202017|Apr 20 - Apr 26","doi":"10.1002/cpt.1862","keywords":["fda","ethics","public policy"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["China","US"],"countries":["China","United States"],"countries_codes":["CHN|China","USA|United States"],"_version_":1664632501392375808,"score":8.518259,"similar":[{"pmid":32293834,"title":"Antiviral treatment of COVID-19","text":["Antiviral treatment of COVID-19","Currently, there is not any specific effective antiviral treatment for COVID-19. Although most of the COVID-19 patients have mild or moderate courses, up to 5%-10% can have severe, potentially life threatening course, there is an urgent need for effective drugs. Optimized supportive care remains the mainstay of therapy. There have been more than 300 clinical trials going on, various antiviral and immunomodulating agents are in various stages of evaluation for COVID-19 in those trials and some of them will be published in the next couple of months. Despite the urgent need to find an effective antiviral treatment for COVID-19 through randomized controlled studies, certain agents are being used all over the world based on either in-vitro or extrapolated evidence or observational studies. The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir and remdesivir will be reviewed here .Nitazoxanide and ivermectin were also included in this review as they have recently been reported to have an activity against SARS-CoV-2 in vitro and are licensed for the treatment of some other human infections.","Turk J Med Sci","Simsek Yavuz, Serap","Unal, Serhat","32293834"],"abstract":["Currently, there is not any specific effective antiviral treatment for COVID-19. Although most of the COVID-19 patients have mild or moderate courses, up to 5%-10% can have severe, potentially life threatening course, there is an urgent need for effective drugs. Optimized supportive care remains the mainstay of therapy. There have been more than 300 clinical trials going on, various antiviral and immunomodulating agents are in various stages of evaluation for COVID-19 in those trials and some of them will be published in the next couple of months. Despite the urgent need to find an effective antiviral treatment for COVID-19 through randomized controlled studies, certain agents are being used all over the world based on either in-vitro or extrapolated evidence or observational studies. The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir and remdesivir will be reviewed here .Nitazoxanide and ivermectin were also included in this review as they have recently been reported to have an activity against SARS-CoV-2 in vitro and are licensed for the treatment of some other human infections."],"journal":"Turk J Med Sci","authors":["Simsek Yavuz, Serap","Unal, Serhat"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293834","week":"202016|Apr 13 - Apr 19","doi":"10.3906/sag-2004-145","keywords":["covid-19","sars-cov-2","antiviral"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Turkey"],"countries":["Turkey"],"countries_codes":["TUR|Turkey"],"e_drugs":["nitazoxanide","remdesivir","Hydroxychloroquine","lopinavir-ritonavir drug combination","Chloroquine","Ivermectin","favipiravir"],"_version_":1664636192600096769,"score":258.397},{"pmid":32243270,"title":"Potential therapeutic agents against COVID-19: What we know so far.","text":["Potential therapeutic agents against COVID-19: What we know so far.","The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19.","J Chin Med Assoc","Lu, Chih-Chia","Chen, Mei-Yu","Chang, Yuh-Lih","32243270"],"abstract":["The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19."],"journal":"J Chin Med Assoc","authors":["Lu, Chih-Chia","Chen, Mei-Yu","Chang, Yuh-Lih"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32243270","week":"202014|Mar 30 - Apr 05","doi":"10.1097/JCMA.0000000000000318","source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["favipiravir","remdesivir","Chloroquine","tocilizumab","Ribavirin","Hydroxychloroquine","sarilumab","lopinavir-ritonavir drug combination"],"_version_":1664638249290694656,"score":215.09563},{"pmid":32256547,"pmcid":"PMC7105280","title":"Clinical trials on drug repositioning for COVID-19 treatment.","text":["Clinical trials on drug repositioning for COVID-19 treatment.","The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus Betacoronavirus, that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants' clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV). It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database. We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution.","Rev Panam Salud Publica","Rosa, Sandro G Viveiros","Santos, Wilson C","32256547"],"abstract":["The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus Betacoronavirus, that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants' clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV). It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database. We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution."],"journal":"Rev Panam Salud Publica","authors":["Rosa, Sandro G Viveiros","Santos, Wilson C"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32256547","week":"202015|Apr 06 - Apr 12","doi":"10.26633/RPSP.2020.40","keywords":["drug repositioning","clinical trials as topic","coronavirus infection","pandemics","pneumonia, viral","virus diseases"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhan","Hubei","China","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Lopinavir","remdesivir","arbidol","Hydroxychloroquine","Chloroquine","favipiravir","Oseltamivir","Methylprednisolone","Ritonavir","Bevacizumab"],"_version_":1664640769738145792,"score":198.46892},{"pmid":32023685,"title":"[Potential antiviral therapeutics for 2019 Novel Coronavirus].","text":["[Potential antiviral therapeutics for 2019 Novel Coronavirus].","The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-beta, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.","Zhonghua Jie He He Hu Xi Za Zhi","Li, H","Wang, Y M","Xu, J Y","Cao, B","32023685"],"abstract":["The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-beta, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Li, H","Wang, Y M","Xu, J Y","Cao, B"],"date":"2020-02-06T11:00:00Z","year":2020,"_id":"32023685","week":"20206|Feb 03 - Feb 09","doi":"10.3760/cma.j.issn.1001-0939.2020.0002","keywords":["2019 novel coronavirus","antiviral therapy","infection"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Ribavirin","Acyclovir","Oseltamivir","lopinavir-ritonavir drug combination","Ganciclovir","Zanamivir","remdesivir"],"_version_":1664640875367497729,"score":191.6031},{"pmid":32246834,"title":"Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.","text":["Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.","An outbreak of 2019-nCoV infection in China has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID-2019. In addition to the recommended antiviral drugs, such as interferon-a, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA-dependent RNA polymerase (RdRp) inhibitors have been registered and initiated. Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials. Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug-drug interactions from the view of drug metabolism. We hope this will be helpful for the design of clinical trials for favipiravir in COVID-2019, as data regarding in vitro virus inhibition and efficacy in preclinical animal studies are still not available.","Clin Pharmacol Ther","Du, Yin-Xiao","Chen, Xiao-Ping","32246834"],"abstract":["An outbreak of 2019-nCoV infection in China has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID-2019. In addition to the recommended antiviral drugs, such as interferon-a, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA-dependent RNA polymerase (RdRp) inhibitors have been registered and initiated. Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials. Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug-drug interactions from the view of drug metabolism. We hope this will be helpful for the design of clinical trials for favipiravir in COVID-2019, as data regarding in vitro virus inhibition and efficacy in preclinical animal studies are still not available."],"journal":"Clin Pharmacol Ther","authors":["Du, Yin-Xiao","Chen, Xiao-Ping"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32246834","week":"202014|Mar 30 - Apr 05","doi":"10.1002/cpt.1844","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Ribavirin","lopinavir-ritonavir drug combination","purine","favipiravir","chloroquine diphosphate"],"_version_":1664638040141725696,"score":191.25293}]}